Because the cornea is an avascular structure that recycles completely within three weeks, treatment pauses provide adequate time for tissue healing. Clinicians recommend prioritizing treatment delays over dose reductions to maintain full dose intensity while allowing ocular side effects to resolve.
Specialist ophthalmology appointments often present major geographic and scheduling hurdles for cancer patients requiring routine toxicity monitoring. Clinicians emphasize that optometrists can reliably perform baseline screenings and initial symptom checks, escalating only severe cases to ophthalmologists.
Clinicians are abandoning watchful waiting in favor of proactive mitigation to avoid fatal pulmonary complications from mirvetuximab. Even asymptomatic patients showing rapid radiographic ground-glass changes can safely receive short, quick steroid tapers rather than the prolonged multi-month regimens used for checkpoint inhibitors.
Adding carboplatin to mirvetuximab produces response levels comparable to single-agent antibody-drug conjugate data rather than marked synergy. Using single-agent ADC therapy in platinum-sensitive recurrence following PARP inhibitor progression provides effective disease control while conserving platinums for later lines.
